A double-blind, randomized, placebo-controlled multi-center, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 [farglitazar] in chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy.

Trial Profile

A double-blind, randomized, placebo-controlled multi-center, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 [farglitazar] in chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Farglitazar (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Oct 2008 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Actual start date changed from Oct 2005 to Nov 2005 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top